NanoVet: Nano drug delivery medium - Commercial opportunity

Opportunity for

• Investors seeking high-impact, scalable innovation in the animal health sector.
• Pharmaceutical companies looking to optimise formulations and extend product patents through enhanced delivery systems.
• Industry partners interested in supporting trials across different animals.
• Research collaborators exploring advanced drug delivery mechanisms for broader applications.

Opportunity description

Industry challenge

Reducing reliance on high volumes of active ingredients is a growing priority in animal health. Traditional drug delivery methods often require excessive doses to achieve therapeutic results — driving up production costs and contributing to environmental concerns, such as active ingredients residues in produce, soils and environment.

There is a clear and urgent need for more targeted, efficient, and sustainable delivery systems that maintain or even enhance efficacy while minimising waste. Improving how pharmaceuticals are absorbed and utilised in the animal's body opens the door to better health outcomes, reduced environmental footprint, and lower operational costs for livestock producers and animal health companies alike.

Current opportunity

Transforming Animal Health with Nanoparticles as a Service (NaaS). NanoVet have developed a novel, patent-pending nanoparticle delivery platform that significantly enhances the performance of active ingredients in animal health pharmaceuticals. This technology enables a reduction of 40–50% in active ingredient usage while maintaining — or even improving — therapeutic efficacy. Applicable across multiple administration formats — including injectables, oral doses, and pour-ons — the platform offers broad versatility and industry appeal.

We are currently seeking commercial partners to support paid pilot programs with both local and global animal health companies aiming to upgrade and differentiate their product portfolios. Interest from leading international pharmaceutical firms is already underway, with our first pilot progressing toward implementation.

This is a first-mover opportunity in a high-growth market segment, where cutting-edge drug delivery science drives efficiency, sustainability, and commercial value. We invite expressions of interest from investors and strategic partners who are ready to engage in the next phase of development and scale-up.

Opportunity background

This delivery technology is an adaptation of a proven human pharmaceutical system that has demonstrated significant performance benefits. Initial trials in livestock species have shown enhanced bioavailability and efficiency. The company is actively securing formal agreements with leading pharmaceutical firms, with expected commercial traction in the coming months.

The business aims to establish Australian-based manufacturing to supply both domestic and international markets, reducing reliance on overseas production. Grant funding opportunities are being pursued to support scale-up efforts and market expansion.

Potential other applications

• Expansion into equine, poultry, and aquaculture industries, where efficient drug delivery is critical.
• Integration with sustainable farming initiatives to minimise pharmaceutical waste and improve animal welfare.
• Development of next-generation formulations in companion animal health, providing cost-effective and more effective treatment options.